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The major innovations in the field of interventional cardi-
ology in the past decade have been the introduction of
stents, now with anti-inflammatory coatings, and platelet
glycoprotein IIb/IIIa inhibitors. Their combined use has
been validated in dedicated trials for patients undergoing
elective coronary revascularization (1–3), but there has been
controversy in the setting of acute myocardial infarction
(MI).
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In this issue of the Journal, Antoniucci et al. (4) of the
Abciximab and Carbostent Evaluation (ACE) trial report
their primary data from the fifth randomized trial of
percutaneous coronary intervention with or without abcix-
imab, the prototypic IIb/IIIa inhibitor, for reperfusion
therapy of acute MI. In this rigorous trial of 400 patients,
the investigators demonstrated superiority of abciximab
compared with a control arm for the primary end point of
death, reinfarction, stroke, and urgent target vessel revascu-
larization at 30 days. The salutary clinical outcomes, which
were durable at six-month follow-up, are further reinforced
by reduction of infarct size using sestamibi scintigraphy and
improved early resolution of electrocardiographic ST-
segment elevation.
The results of ACE need to be placed in context with the
four previous trials: ReoPro and Primary PTCA Organiza-
tion and Randomized Trial (RAPPORT) (5), Intracoronary
Stenting and Antithrombotic Regimen-2 (ISAR-2) (6),
Abciximab Before Direct Angioplasty and Stenting in
Myocardial Infarction Regarding Acute and Long-term
Follow-up (ADMIRAL) (7), and Controlled Abciximab
and Device Investigation to Lower Late Angioplasty Com-
plications (CADILLAC) (8). In Figure 1, 30-day end
points for the five trials are displayed. In pooling these data,
which do not demonstrate any intertrial heterogeneity, there
is an overall 46% reduction in death, reinfarction, and target
vessel revascularization; a 34% reduction in death or rein-
farction; and a 26% reduction in death. These results
provide strong and consistent evidence of benefit for ad-
junctive use of abciximab with catheter-based reperfusion
for MI.
Yet, until the ACE trial was performed, there had been
debate in this field because of the results of the largest trial
did not support the benefit of abciximab at the primary end
point timing of six months. In fact, in the CADILLAC
trial, there were more deaths and reinfarctions, albeit not
statistically significant, among the stent-abciximab group
compared with the stent control group at six months. The
explanation for why this occurred, leading to particular
confusion in this field, needs to be addressed. As the
chairmen of the other three trials, we will attempt to shed
light on this critical question.
Unlike the principal outcomes for the five trials at 30
days, which were remarkably concordant, the study designs
and methodology were quite variable. In only two trials,
RAPPORT and ADMIRAL, were there double-blind
placebo controls. In both of these trials, abciximab study
drug was encouraged to be given as early as possible after
diagnosis, before the patient’s entry to the cardiac catheter-
ization laboratory. This was achieved only in 20% of the
patients in RAPPORT, whereas in ADMIRAL 26% re-
ceived the study drug in the emergency room or in the
ambulance, and all patients had the treatment started before
sheath insertion. This design, with an administration always
performed before the angiogram, led to benefits of similar
magnitude in high-risk versus low-risk patients (shock vs.
no shock; anterior vs. other MI; young vs. elderly; diabetes
vs. no diabetes). The other three trials did not allow for use
of abciximab before coronary angiography, which appears to
have attenuated the potential benefit of abciximab or limit
its effects to the high-risk patients only. To understand the
impact of early abciximab therapy, it is noteworthy that in
the ADMIRAL trial there was a dramatic effect of abcix-
imab on clot structure as analyzed in a simultaneous
substudy by Collet et al. (9) and a striking 89% reduction of
the six-month end point with the use of early abciximab.
Furthermore, in that trial, the Thrombolysis In Myocardial
Infarction (TIMI) grade 3 flow before the procedure was
enhanced more than three-fold among the patients with
ST-segment elevation myocardial infarction (STEMI) who
were randomized to receive abciximab. These results have
been recently confirmed with tirofiban when administered
in the emergency room before transfer for primary percuta-
neous coronary intervention compared with a later admin-
istration in the catheterization laboratory (10). Beyond the
clinical benefits linked to an early open artery hypothesis,
better flow in the culprit artery allows better visualization of
length of the lesion, the side branches, the presence of
thrombus, and the distal artery and may facilitate all steps of
the procedure, including direct stenting, which has been
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Figure 1. (A) Death, reinfarction, and target vessel revascularization (TVR) at 30 days. Two trials included stroke in the composite end point (ACE,
CADILLAC), but the incidence was quite low. (B) Death or reinfarction at 30 days. (C) Death at 30 days. ACE  Abciximab and Carbostent Evaluation;
ADMIRAL  Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-term Follow-up; CADILLAC 
Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications; CI  confidence interval; ISAR-2  Intracoronary Stenting and
Antithrombotic Regimen-2; MI  myocardial infarction; OR  odds ratio; RAPPORT  ReoPro and Primary PTCA Organization and Randomized Trial.
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associated with less slow flow and better ST-segment
resolution (11). How much the early administration of
IIb/IIIa inhibitors in STEMI patients undergoing percuta-
neous coronary intervention can limit thrombus extension,
shorten the time of procedure, reduce the total length of
stent implanted in the culprit artery, reduce distal emboli-
zation, and finally impact clinical outcome is difficult to
quantify but obviously no less cost-effective compared with
a later administration (12).
The entry criteria varied among the five protocols with
respect to key features, such as enrollment of patients with
cardiogenic shock that was supported in ISAR-2, ADMI-
RAL, and ACE. This is quite important because the risk of
the patients varied substantially, as seen in Figure 1.
Interestingly, the 30-day composite end point for CADIL-
LAC was 6.8% in the control arm, but in each of the other
four trials it exceeded 10%, reflecting the risk of the control
cohorts in each trial. The low risk observed in CADILLAC
was not only driven by the clinical exclusion criteria but also
by the multiple angiographic exclusion criteria eliminating
the anatomically difficult cases that would benefit the most
from the drug. This is clearly another consequence of a
strategy of late administration. It is this particular feature
that likely was dominant in the explanation of why signif-
icant benefit for abciximab was not supported in the
CADILLAC trial. In such a low-risk population, the
opportunity for demonstrating benefit, as compared with
the play of chance of clinical outcomes and type II () error,
most likely accounts for the disparity compared with the
other four smaller trials. Moreover, the definitions for end
points varied among the trials, such as enzymatic criteria for
diagnosis of reinfarction, and whether this end point was
adjudicated by an event committee blinded to the treatment
assignment. Finally, interpreting the lack of benefit of the
study drug tested in a factorial design (the other objective
being the comparison stent-balloon) in the only subgroup of
stented patients remains questionable.
The extended follow-up data for the five trials has
demonstrated an interesting pattern. In all of the trials
except CADILLAC, there was support for abciximab treat-
ment benefit for reduction of death or reinfarction at six
months follow-up, and in both ADMIRAL and ACE the
differences were statistically significant (Fig. 2). The pres-
ervation of the initial clinical benefit at three-year follow-up
in ADMIRAL confirms further the need for this early
treatment in a population representative of the risk observed
in the real world (13). These findings further underscore the
difficulty of interpreting durability of a treatment effect
when the population exposed to the intervention being
tested is one of low risk.
Beyond the five trials of percutaneous coronary revascu-
larization with or without abciximab, there has been further
validation in randomization of lytic strategies (recombinant
tissue-type plasminogen activator with or without abcix-
imab) compared with stenting with abciximab. These trials,
Stent Versus Thrombolysis for Occluded Coronary Arteries
in Patients with Acute Myocardial Infarction (STOPAMI)
I and II (14,15), have both shown improved clinical out-
comes and infarct size reduction for the strategy of stenting
with abciximab compared with pharmacologic reperfusion
therapy. Along with the recent results from randomized
trials comparing transfer of patients with acute MI to
specialized centers to perform catheter-based reperfusion,
compared with fibrinolytic therapy (16,17), it becomes clear
that angioplasty or stenting with abciximab is the preferred
reperfusion strategy. Stenting has indeed been shown to be
preferred over balloon angioplasty (8), but there are ana-
tomical situations in which stenting is not logistically
feasible or advisable. Furthermore, the decision whether to
use abciximab should ideally be made before definition of
the coronary anatomy, irrespective of whether the infarct-
related artery is suitable for stenting or balloon angioplasty.
We believe that the results of the ACE trial, amalgam-
ated with the other catheter-based reperfusion trials, pro-
vide robust evidence for the use of abciximab as a standard
adjunctive therapy with catheter-based reperfusion and do
not justify a different level of recommendation for the use of
glycoprotein IIb/IIIa inhibitors in STEMI according to
whether or not a stent is implanted (18). Considering stent
plus abciximab as the gold standard for STEMI, undergoing
mechanical reperfusion should impact routine practice as
well as the control arms of future trials designed to test new
strategies, such as full thrombolysis or combined therapy en
route to the catheterization laboratory. The data available
indicate that early use, before visualization of the coronary
arteries, will be associated with the most favorable clinical
outcomes. Although it may be possible to replicate the
favorable findings with other IIb/IIIa inhibitors, the only
available data to date have been accrued with abciximab.
Unless or until there are new data available, we should
regard catheter-based reperfusion with adjunctive abciximab
therapy as the preferred reperfusion therapy for acute MI.
Figure 2. Rate of death and myocardial infarction (MI) at 6 months for five
clinical trials of percutaneous coronary revascularization with and without
abciximab. Trial abbreviations as in Figure 1.
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